{"schema_version":"secwatch.filing_event.v1","accession":"0000313143-25-000015","form_type":"8-K","ticker":"HAE","cik":"0000313143","company_name":"HAEMONETICS CORP","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.935532+00:00","generated_at":"2026-05-25T22:10:27.522058+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Haemonetics appoints Frank Chan as EVP COO, promotes Roy Galvin to CCO","bullets":["Frank Chan appointed EVP COO effective April 7, 2025; oversees R&D, regulatory, global manufacturing & supply chain.","Roy Galvin promoted to EVP, Chief Commercial Officer effective immediately; adds Global Hospital business to his remit.","Chan's compensation: $550k base salary, 80% target bonus, $1.6M long-term equity award, plus $350k sign-on bonus.","Chan most recently President of Medtronic's Acute Care & Monitoring business; 25+ years experience.","Stewart Strong continues as President, Global Hospital through April 1, then advisor to CEO for transition."],"urls":{"canonical":"https://secwatch.observer/filing/0000313143-25-000015","json":"https://secwatch.observer/filing/0000313143-25-000015.json","markdown":"https://secwatch.observer/filing/0000313143-25-000015.md","text":"https://secwatch.observer/filing/0000313143-25-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/313143/000031314325000015/0000313143-25-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/313143/000031314325000015/hae-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T22:10:27.522058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dcaf9311af","claim":"Frank W. Chan was appointed as Executive Vice President, Chief Operating Officer at HAEMONETICS CORP.","evidence_excerpt":"On March 3, 2025, Haemonetics Corporation (the “Company”) announced the appointment of Frank W. Chan, Ph.D. as its Executive Vice President, Chief Operating Officer, effective April 7, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/313143/000031314325000015/0000313143-25-000015-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President, Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}